Loading clinical trials...

Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder | Clinical Trials | Clareo Health

COMPLETEDNA

Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder

Prospective Randomized Trial Comparing Unilateral and Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder

NCT01558856•Centre Hospitalier Universitaire de Nīmes

View on ClinicalTrials.gov

Summary

The primary objective of this study is to compare the efficacy of unilateral and bilateral neuromodulation tests at 1 month.

Detailed Description

The secondary objectives of this study are to compare the following elements between a group of patients undergoing unilater modulation tests (standard procedure) and a group of patients undergoing bilateral neuromodulation tests (experimental procedure) (at 1 month): Pollakiuria, pad use, urge incontinence, symptom severity, % of patients not eligible for an implant, debimetry, tolerance, complications, quality of life.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•The patient must have given his/her informed and signed consent
•The patient must be insured or beneficiary of a health insurance plan
•The patient is available for 1 month of follow-up
•The patient understands and reads French
•The patient has symptoms of overactive bladder resistant to first-line treatments (physiotherapy, anticholinergics)
•The patient suffers from an overactive bladder confirmed by a urodynamic panel
•The patient suffers from an overactive bladder unassociated with bladder obstruction as confirmed by flowmetry
•The patient has primary (idiopathic) overactive bladder primary with normal urinalysis, abdominal and pelvic ultrasound, urine cytology + / - cystoscopy
•The patient has no bleeding disorders, or the disorder is properly controlled after treatment

Exclusion Criteria

•The patient is participating in another study
•The patient is in an exclusion period determined by a previous study
•The patient is under judicial protection, under tutorship or curatorship
•The patient refuses to sign the consent
•It is impossible to correctly inform the patient
•The patient is pregnant, parturient, or breastfeeding
•Overactive bladder associated with bladder obstruction as determined by flowmetry
•Overactive bladder unconfirmed by urodynamic panel
•Overactive bladder secondary to another condition:
•vesical: urolithiasis, bladder polyp, interstitial cystitis
+3 more criteria

Locations (6)

Clinique Beau Soleil

Montpellier, France

CHU de Nantes - Hôtel Dieu

Nantes, France

CHU de Nîmes - Hôpital Universitaire Carémeau

Nîmes, France

APHP - Groupe Hospitalier Pitié-Salpetrière

Paris, France

CHU de Rouen - Hôpital Charles Nicolle

Rouen, France

CHRU de Toulouse - Hôpital de Rangueil

Toulouse, France

Key Dates

Start Date

October 23, 2012

Primary Completion Date

September 20, 2017

Completion Date

January 23, 2018

Last Updated

November 21, 2025

Enrollment

ACTUAL participants

Conditions

Urinary Bladder, Overactive

Interventions

Unilateral electrode placement and testing

PROCEDURE

Bilateral electrode placement and testing

PROCEDURE

Comparison of the Efficacy of Perineal and Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladder

NCT07366918

Urinary Bladder, Overactive

View study

RECRUITING

Elastographic Assessment of Suburethral Tissue in Continent and Incontinent Women

NCT06933407

Urinary IncontinenceUrinary Incontinence, Stress+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 21, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Unilateral Versus Bilateral Neuromodulation Tests in the Treatment of Refractory Idiopathic Overactive Bladder

Inclusion Criteria

Exclusion Criteria

Comparison of the Efficacy of Perineal and Intravaginal Electrical Stimulation in Women With Idiopathic Overactive Bladder

Elastographic Assessment of Suburethral Tissue in Continent and Incontinent Women

NXT Post-Market Clinical Follow-up

A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug

A Study of YM178 in Subjects With Symptoms of Overactive Bladder

Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents